The deal priced below last closing price of $3.76. Oppenheimer and JMP Securities are acting as joint book running managers for the offering.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INO:
- Inovio announces common stock and warrants offering, no amount given
- Inovio’s INO-3107 shows efficacy in Phase 1/2 RRP trial
- Inovio price target lowered to $15 from $33 at Oppenheimer
- Inovio price target lowered to $5 from $12 at H.C. Wainwright
- Inovio Pharmaceuticals Advances DNA Medicine Development